Redefining clinical research: how AI and digital innovation are putting patients at the center

As per a recent research, around 80 percent of clinical trials fail to meet their original enrollment timelines. Such delays are not only significantly expensive, but they also often extend the wait for patients in urgent need of life-changing treatments. Despite substantial funding and meticulous planning across the pharmaceutical sector, clinical trial delays are widespread.

In addition, clinical development already accounts for one of the largest components of the total cost involved in the development of a new drug. Bringing a single new molecular entity to approval now typically costs between $2 billion and $2.6 billion, once capital costs and the rate of clinical failures are factored in across a development lifecycle that can span 10 to 15 years. 

The cost of clinical trial failures extends beyond just the balance sheet. Stalled trials mean delayed treatments, leaving vulnerable patients in limbo as health and quality of life hang in the balance. 

Smarter trials by design

AI and advanced analytics are making a mark in improving trial design upstream, even before any patient is recruited into the trial, with a shift from intuition-led to data-led trial design. 

McKinsey estimates suggest that in pharma, around 75 to 85 percent of workflows have at least some tasks that agents could handle, which could help free up 25 to 40 percent of capacity. 

Identifying optimal patient populations is one of the toughest parts of planning a clinical trial. The process is simplified with predictive modeling by analyzing data from thousands of past trials and patient databases. Protocol optimization is used to cut through the complexity of trials, and clinical trial simulation tools often help anticipate points where trials could break or fail.

Reaching more patients, faster

Clinical trial models typically depended on patients who lived near major research centers and could make frequent visits to the hospital. This meant that trial populations were mainly from urban areas staying close to well-resourced hospitals, thus often excluding people who lived in rural areas and had mobility constraints. This resulted in an imbalance in the diversity of the population taking part in clinical trials. Decentralized trials are helping with correcting that imbalance by opening up trials even to those who live in remote areas.

Telemedicine, electronic consent, remote monitoring, and wearables increasingly make real-time data capture possible, closing much of the gap that once required on-site monitoring. This has led to trials that are more flexible, patient-centric, and diverse.

Monitoring and compliance in real time

Before clinical trials went digital, a monitor had to physically travel to each trial location to verify paper records, confirm data accuracy, and catch protocol violations, if any. Earlier, errors or deviations could compound for few weeks before they were noticed. AI-based monitoring has virtually almost eliminated this delay.

AI monitoring tools reduce dependence on periodic site visits and offer continuous, real-time insights. They enhance risk assessment in clinical trials. Such tools can help identify early warning signs of disease progression or adverse events, enabling proactive clinical management and reducing the probability of serious safety events. Traditional monitoring typically delivers 70 to 75 percent sensitivity for adverse event detection. On the other hand, AI-based digital biomarker systems deliver around 90 percent sensitivity with real-time alerts.

For regulators and sponsors, the usage of AI-based monitoring means faster and cleaner data, shorter review timelines, and a more transparent research process. Regulatory bodies are also increasingly receptive to these approaches, indicating that the regulatory environment is open to this shift.

As per a research by McKinsey, it is estimated that AI agents could give pharma companies incremental growth of 5-13 percentage points, with an EBITDA increase of 3.4 to 5.4 percentage points. The direction clinical trials are heading in, is fairly clear: shorter timelines, broader patient access, and data that regulators and sponsors can actually trust. Just buzzwords will not work anymore – this transformation will take real investment in better statistical methods and AI tools.

The post Redefining clinical research: how AI and digital innovation are putting patients at the center appeared first on Express Pharma.